Article

Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries

Department of Clinical Psychology, University of Bergen, Bergen, Hordaland, Norway
Sleep Medicine (Impact Factor: 3.1). 08/2005; 6(4):307-12. DOI: 10.1016/j.sleep.2005.03.008
Source: PubMed

ABSTRACT To estimate prevalence and severity (using the International Restless Legs Syndrome Study Group Rating Scale (IRLS)) and to identify risk factors of restless legs syndrome (RLS).
Population-based cross-sectional study; 2005 randomly selected adults 18 years and above participated in a telephone interview in Norway and Denmark, employing the next-birthday technique.
Of the cross-section, 11.5% fulfilled the diagnostic criteria for RLS. Half of these reported the symptoms as moderate to very severe. Mean duration of the complaint was 10 years. Prevalence was higher in females than in males (13.4 vs 9.4%) and lowest in the youngest age group (18-29 years, 6.3%). From 30 years and above, no clear age-related difference was seen. Main predictors of RLS were insomnia (odds ratios: 1.71-3.16) and symptoms of periodic limb movements in sleep (3.20-7.85). The response rate was 47%, making the results less reliable.
This study indicates that there is a high occurrence of RLS among adults. Main predictors are insomnia and periodic limb movements in sleep.

0 Followers
 · 
199 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Restless legs syndrome (RLS) is a neurological disorder characterized by an urge to move the legs often accompanied by unpleasant sensations. Symptoms appear during periods of rest or inactivity, particularly in the evening and at night, and are usually relieved by movement. The prevalence of RLS among Whites is approximately 5-15%. RLS can be distinguished into primary and secondary forms. Most patients (70-80%) are affected by the primary form of RLS. The uncomfortable sensations related to RLS often cause a minimal discomfort, thus a therapeutic approach is not necessary. However, almost 3% of the general population reports to be affected by severe symptoms of RLS, requiring pharmacological treatment. Secondary forms of RLS are relieved by the remission of the underlying clinical condition. Dopamine agonists are considered to be first-line treatments for primary RLS. Rotigotine is a nonergoline dopamine agonist with selectivity for D1, D2 and D3 receptors. It is administered once a day in the form of an adhesive matrix patch. The efficacy and safety of the drug in patients with primary RLS has been demonstrated by four clinical trials using dosages of 0.5, 1, 2, 3 and 4 mg/24 h. A dose-response relationship was observed between the dosages of 0.5 and 3 mg/24 h. Side effects were usually mild, the most frequent being skin reaction at the site of patch application. More trials are ongoing and results will soon be published for the long-term (5 years) treatment of RLS with rotigotine transdermal patches. Rotigotine is a promising drug for the treatment of RLS. Its continuous delivery throughout 24 h makes it especially indicated for those cases also presenting daytime symptoms, and for those presenting the so-called augmentation syndrome after prolonged treatment with L-dopa or dopamine agonists.
    Therapeutic Advances in Neurological Disorders 07/2010; 3(4):241-8. DOI:10.1177/1756285610374679
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Restless legs syndrome (RLS) is a common neurological disorder characterized by an irresistible urge to move the legs, usually accompanied or caused by uncomfortable sensations in the legs. Symptoms are worse in the evening or at night than during the day and generally begin or worsen during periods of rest or inactivity. The chronic sleep disturbance often associated with RLS is likely due, at least in part, to the circadian nature of the symptoms. The relationship between disturbed sleep and reduced daytime functioning is well known and thus the accurate diagnosis and effective management of RLS is imperative.
    Neuropsychiatric Disease and Treatment 01/2007; 2(4):513-9. DOI:10.2147/nedt.2006.2.4.513 · 2.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZET Amaç: Bu çal›flmada, Bursa ili Orhangazi ilçesinde yaflayan, 40 yafl ve üzeri popülasyondaki hareket bozukluklar›n›n prevalans oranla-r›n›n bildirilmesi amaçland›. Hastalar ve Yöntem: Çal›flmam›z üç fazl› olarak planland›. Faz I'de; 1256 olgu halk sa¤l›¤› ve nöroloji asistanlar› taraf›ndan kap›-ka-p›, ev ziyaretleri fleklinde k›sa anket formu doldurularak tarand› ve 404 flüpheli hareket bozuklu¤u olgusu tan›mland›. fiüpheli olgula-r›n 131'i faz II'de de¤erlendirilebildi ve bu olgular hareket bozukluklar› uzmanlar› taraf›ndan görülerek tremor, huzursuz bacak send-romu, hemifasiyal spazm ve distoni tan›lar› için kulland›¤›m›z skalalar doldurularak video kay›tlar› al›nd›. Faz III'te tüm video görüntü-leri hareket bozukluklar› uzmanlar› taraf›ndan izlendi ve son tan› konusunda fikirbirli¤ine var›ld›. Bulgular: Prevalans oranlar›, huzursuz bacak sendromu için; n= 60, %9.71, esansiyel tremor için; n= 21, %3.34, ilerlemifl fizyolojik tremor için; n= 26, %4.14, Parkinson hastal›¤› için; n= 14, %2.23, hemifasiyal spazm için; n= 4, %0.82 ve distoni için; n= 2, %0.41 olarak bulundu. Yorum: Esansiyel tremor, hareket bozukluklar› aras›nda en s›k görülmesine ra¤men bizim çal›flmam›zda huzursuz bacak sendromu prevalans›n›n esansiyel tremor prevalans›ndan daha fazla oldu¤u gözlendi. Anahtar Kelimeler: Esansiyel tremor, huzursuz bacak sendromu, Parkinson hastal›¤›, hareket bozukluklar›.